Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, scheduled for July 16, 2026, in Boston. The company will be featured in a fireside chat at 12:20 p.m. local time that day.
This summit is a dedicated healthcare conference organized by B. Riley Securities, concentrating on innovations within the fields of neurology, muscle disorders, and ophthalmology. The event is structured around three thematic tracks: Mind, Muscle, and Vision. Cardiol will be part of the Muscle Track, which highlights companies developing therapies for rare neuromuscular, cardiology, and inflammatory indications.
Cardiol Therapeutics is a late-stage life sciences company focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule candidate, CardiolRx™, functions by modulating the inflammasome pathway, which plays a significant role in the development of inflammation and fibrosis associated with conditions such as myocarditis, pericarditis, and heart failure.
The company is currently progressing its MAVERIC program, which is evaluating the efficacy of CardiolRx™ for the treatment of recurrent pericarditis. This initiative includes the completed Phase II MAVERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial. In April 2026, the company reported that patient enrollment for the MAVERIC trial had reached 75%, with the targeted recruitment expected to be completed by the end of the second quarter. The U.S. Food and Drug Administration has granted CardiolRx™ Orphan Drug designation for the treatment of pericarditis, including its recurrent form.
Furthermore, Cardiol is developing CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Heart failure represents one of the leading causes of death and hospitalization in the developed world, with associated annual healthcare costs in the United States exceeding $30 billion.
Companies attending the summit are selected by B. Riley Securities' equity research team and span the fields of psychiatry, neurology, neuromuscular disorders, cardiology, and ophthalmology. Institutional investors will have the opportunity to schedule one-on-one or small group meetings with company management teams to gain further insight into their clinical development progress.
Comments